PortfoliosLab logo
PortfoliosLab logo
Tools
Portfolios
Screeners
Discussions
EDIT vs. VERV
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between EDIT and VERV is 0.39, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

EDIT vs. VERV

Last updated May 31, 2025

Compare and contrast key facts about Editas Medicine, Inc. (EDIT) and Verve Therapeutics, Inc. (VERV).

Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: EDIT or VERV.

Performance

EDIT vs. VERV - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Editas Medicine, Inc. (EDIT) and Verve Therapeutics, Inc. (VERV). The values are adjusted to include any dividend payments, if applicable.

Loading data...

Key characteristics

Sharpe Ratio

EDIT:

-0.52

VERV:

-0.14

Sortino Ratio

EDIT:

-0.56

VERV:

0.47

Omega Ratio

EDIT:

0.93

VERV:

1.05

Calmar Ratio

EDIT:

-0.68

VERV:

-0.16

Martin Ratio

EDIT:

-1.15

VERV:

-0.49

Ulcer Index

EDIT:

59.01%

VERV:

30.55%

Daily Std Dev

EDIT:

129.34%

VERV:

95.98%

Max Drawdown

EDIT:

-98.92%

VERV:

-95.99%

Current Drawdown

EDIT:

-98.10%

VERV:

-93.99%

Fundamentals

Market Cap

EDIT:

$153.19M

VERV:

$410.06M

EPS

EDIT:

-$3.04

VERV:

-$2.11

PS Ratio

EDIT:

4.27

VERV:

6.88

PB Ratio

EDIT:

2.45

VERV:

0.87

Total Revenue (TTM)

EDIT:

$35.84M

VERV:

$59.61M

Gross Profit (TTM)

EDIT:

$26.78M

VERV:

$21.52M

EBITDA (TTM)

EDIT:

-$175.04M

VERV:

-$203.33M

Returns By Period

In the year-to-date period, EDIT achieves a 35.43% return, which is significantly higher than VERV's -21.10% return.

EDIT

YTD

35.43%

1M

4.24%

6M

-23.21%

1Y

-66.73%

3Y*

-46.75%

5Y*

-42.38%

10Y*

N/A

VERV

YTD

-21.10%

1M

-21.52%

6M

-20.68%

1Y

-13.42%

3Y*

-33.54%

5Y*

N/A

10Y*

N/A

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Editas Medicine, Inc.

Verve Therapeutics, Inc.

Go deeper with the Portfolio Analysis tool — backtest performance, assess risk, compare to benchmarks, and more

Risk-Adjusted Performance

EDIT vs. VERV — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.
EDIT
The Risk-Adjusted Performance Rank of EDIT is 1818
Overall Rank
The Sharpe Ratio Rank of EDIT is 2121
Sharpe Ratio Rank
The Sortino Ratio Rank of EDIT is 2020
Sortino Ratio Rank
The Omega Ratio Rank of EDIT is 2222
Omega Ratio Rank
The Calmar Ratio Rank of EDIT is 99
Calmar Ratio Rank
The Martin Ratio Rank of EDIT is 1919
Martin Ratio Rank
VERV
The Risk-Adjusted Performance Rank of VERV is 4444
Overall Rank
The Sharpe Ratio Rank of VERV is 4242
Sharpe Ratio Rank
The Sortino Ratio Rank of VERV is 4949
Sortino Ratio Rank
The Omega Ratio Rank of VERV is 4747
Omega Ratio Rank
The Calmar Ratio Rank of VERV is 4040
Calmar Ratio Rank
The Martin Ratio Rank of VERV is 4040
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

EDIT vs. VERV - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Editas Medicine, Inc. (EDIT) and Verve Therapeutics, Inc. (VERV). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current EDIT Sharpe Ratio is -0.52, which is lower than the VERV Sharpe Ratio of -0.14. The chart below compares the historical Sharpe Ratios of EDIT and VERV, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Loading data...

Go to the full Sharpe Ratio tool to analyze any stock or portfolio. Customize time frames, set your own risk-free rate, and more

Dividends

EDIT vs. VERV - Dividend Comparison

Neither EDIT nor VERV has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

EDIT vs. VERV - Drawdown Comparison

The maximum EDIT drawdown since its inception was -98.92%, roughly equal to the maximum VERV drawdown of -95.99%. Use the drawdown chart below to compare losses from any high point for EDIT and VERV.

Loading data...

Go to the full Drawdowns tool for more analysis options, including inflation-adjusted drawdowns, and more

Volatility

EDIT vs. VERV - Volatility Comparison

Editas Medicine, Inc. (EDIT) has a higher volatility of 31.81% compared to Verve Therapeutics, Inc. (VERV) at 27.05%. This indicates that EDIT's price experiences larger fluctuations and is considered to be riskier than VERV based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Loading data...

Financials

EDIT vs. VERV - Financials Comparison

This section allows you to compare key financial metrics between Editas Medicine, Inc. and Verve Therapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.

Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities

0.0010.00M20.00M30.00M40.00M50.00M60.00M20212022202320242025
4.66M
32.98M
(EDIT) Total Revenue
(VERV) Total Revenue
Values in USD except per share items